Biocircuits Corporation Strengthens Proprietary Position in Diagnostic Testing Market

Strategic Insights

Aug 14, 1995 — 1 min read

Biocircuits Corporation, a leading developer of diagnostic testing systems, has announced the receipt of two additional patents from the U.S. Trade and Patent office, further solidifying its position in the diagnostic testing market. The patents cover improvements to the company's lipid/polymer technology, which is used in its immunodiagnostic testing system, the IOS point-of-care system. These new patents expand the scope of the company's existing patents and provide a wider range of applications for the lipid/polymer technology, offering opportunities for out-licensing or co-development with strategic partners.

Key Takeaways:

Biocircuits Corporation has been issued two additional patents by the U.S. Trade and Patent office for improvements to its lipid/polymer technology.
The patents cover enhanced immunoassay methods and simplified assay procedures, expanding the scope of the company's existing patents.
The lipid/polymer technology is used in the company's immunodiagnostic testing system, the IOS point-of-care system, designed for use in physicians' offices and other point-of-care sites.
The company has a total of seven patents and seven pending patents for its lipid/polymer technology.
Biocircuits plans to develop an array of immunodiagnostic assays for the IOS system and expects to expand its test menu to incorporate other frequently requested immunodiagnostic tests.
The company filed a 510(k) pre-market notification for the IOS system and two initial assays, T4 and T Uptake, for determining thyroid dysfunction in June 1995.

Statistics:

Total patents held by Biocircuits: 7
Total patents pending for Biocircuits: 7
Number of patents issued to Biocircuits in this announcement: 2 (patent numbers 5,415,999 and 5,427,915)
Number of assays developed by Biocircuits: 2 (T4 and T Uptake)
Number of tests expected to be added to the IOS system: multiple (expanded test menu)

Sources:

"Biocircuits Corporation Receives Two Additional Patents for Assay Technology" (PRNewswire, Aug. 15, 1995)
Biocircuits Corporation's press release (Aug. 15, 1995)

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients